Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
In the face of Keytruda’s (pembrolizumab) increasing dominance in the lung cancer market, Ono Pharmaceutical President Gyo Sagara says his company has a three-pronged recipe to have Opdivo (nivolumab) regain ground in the PD-1 inhibitor space, with one being label…
To read the full story
Related Article
- Ono’s Drug Sales Skid in Q1, but Opdivo Royalties Underpin Earnings
August 2, 2019
- Ono Racks Up 19% Revenue Rise on Positive Opdivo Sales
November 2, 2018
- Opdivo Sales Up 15% in April-June: Ono
August 2, 2018
- Opdivo Sales Dip 13% despite 1.5-Fold Volume Growth: Ono
May 11, 2018
BUSINESS
- Medii, Pediatric Neurology Society Build System to Support Elevidys Use
April 24, 2026
- Oncolys’ OBP-301 Wins US Fast Track Designation
April 24, 2026
- Rituxan Biosimilar Expands Nephrotic Syndrome Indication in Japan
April 24, 2026
- Gilead Files Trodelvy-Keytruda Combo for 1L TNBC in Japan
April 24, 2026
- Genmab Targets 2027 US Debut for 2 Cancer Drugs, CEO Eyes Blockbuster Potential
April 23, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…